Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Clinical trial NCT04484818 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04484818
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2026-06-09
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.